Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
NCT ID: NCT01485601
Last Updated: 2024-02-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
121 participants
INTERVENTIONAL
2011-12-07
2012-08-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
NCT04830345
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
NCT01271452
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
NCT05496335
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
NCT02303002
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
NCT01189760
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MT10109
Clostridium botulinum toxin type A
MT10109
Single dose intramuscular injection MT10109 vs Botox®
Botox (registered trade mark)
Clostridium botulinum toxin type A
MT10109
Single dose intramuscular injection MT10109 vs Botox®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MT10109
Single dose intramuscular injection MT10109 vs Botox®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women of childbearing potential must have a negative serum pregnancy test at screening
Exclusion Criteria
* Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication
* Patients with an anaphylactic response history to botulinum toxin type A.
* Patients who have been administered botulinum toxin type A within the previous 6 months.
* Pregnant or lactating women.
* Participation in any research study involving drug administration within 90 days preceding enrollment.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medy-Tox
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Foley, Doctor
Role: PRINCIPAL_INVESTIGATOR
Austrailia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Melbourne, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT-GPRT-GL01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.